- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Azithromycin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2000
- U.S. locations
- 19
- States / cities
- San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
- Interventions
- Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo
- Biological · Drug
- Lead sponsor
- Serum Life Science Europe GmbH
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Pneumococcal Disease Prevention
- Interventions
- phone call from nurses - informational only
- Behavioral
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 7,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Pneumococcal Infections
- Interventions
- 13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,141 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 19 more
- Conditions
- Influenza, Infections, Pneumococcal
- Interventions
- Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call, Arm 5: IVR call
- Other
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2000
- U.S. locations
- 15
- States / cities
- San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
- Conditions
- PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
- Interventions
- 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine, Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more